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Abstract. Alzheimer’s disease (AD) is a devastating form of dementia that imposes a severe burden on health systems and
society. Although several aspects of AD pathogenesis have been elucidated over the last few decades, many questions still need
to be addressed. In fact, currently available medications only provide symptomatic improvement in patients with AD without
affecting disease progression. The -adrenergic receptor (-AR) system can be considered a possible target that deserves further
exploration in AD. The central noradrenergic system undergoes substantial changes in the course of AD and -ARs have been
implicated not only in amyloid formation in AD brain but also in amyloid-induced neurotoxicity. Moreover, clinical evidence
suggests a protective role of -AR blockers on AD onset. In addition to that, post-receptor components of -AR signaling seem
to have a role in AD pathogenesis. In particular, the G protein coupled receptor kinase 2, responsible for -AR desensitization
and downregulation, mediates amyloid-induced -AR dysfunction in neurons, and its levels in circulating lymphocytes of
AD patients are increased and inversely correlated with patient’s cognitive status. Therefore, there is an urgent need to gain
further insight on the role of the adrenergic system components in AD pathogenesis in order to translate preclinical and clinical
knowledge to more efficacious prognostic and therapeutic strategies.
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Alzheimer’s disease (AD) is the most common form
of age-related dementia, affecting more than 35 mil-
lion people in the world and about 4.4% of the elderly
population [1]. It is a progressive neurodegenerative
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disorder characterized by various mental dysfunctions
including cognitive impairment, emotional instability,
and changes in personality [2]. In advanced disease,
diffuse cerebral atrophy with widened sulci and ven-
tricles enlargement are observed. Microscopically, loss
of selected populations of neurons occurs. Neuronal
degeneration in AD affects different subcortical nuclei:
nucleus basalis of Meynert, the major source of the
neurotransmitter acetylcholine; locus coeruleus (LC)
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which produces norepinephrine; substantia nigra pars
compacta, a source of dopamine; and dorsal raphe
nucleus, which releases serotonin. Each of these nuclei
projects to wide areas of cerebral cortex or basal gan-
glia, thus integrating inputs from different sources and
modulating several physiological processes (arousal
and sleep, blood pressure, attention and vigilance,
memory and learning, mood and aggression).
Several molecular lesions have been detected in AD.
Among them, the deposition of amyloid plaques, which
are largely composed of amyloid- (A), is a major
characteristic of AD neuropathology and considered
to be the primary cause of the disease. A is gen-
erated from the amyloid- protein precursor (APP)
via sequential cleavages by - and -secretases. The
-secretase is pivotal, because mutations in the cat-
alytic subunit presenilin-1 account for most cases of
familial AD [3].
Multiple lines of evidence suggest that, either result-
ing from an inherited genetic mutation or caused by an
environmental insult, over-accumulation of A in AD
brain is one of the common points in which multiple
initiating pathways may converge.
Moreover, neurodegenerative diseases such as AD
are associated with microvascular dysfunction, neu-
rovascular degeneration, and alterations in blood-brain
barrier function. Such deficits impair the clearance of
neurotoxic molecules, such as A, that accumulate in
brain and reduce the brain’s supply of oxygen and nutri-
ents. Thus, vascular dysfunction is tightly linked to
neuronal dysfunction in AD [4].
However, despite the multiple hypothesis on AD
pathogenesis that can contribute to the onset and the
progression of the disease, the current pharmacological
treatment is mainly based on drugs that increase brain
acetylcholine levels, according to evidence derived
from studies on the nucleus basalis neuronal loss in
AD. In any case, these molecules induce only a tem-
porary and symptomatic improvement in patients with
AD [5]. Thus, there is an increasing interest in explor-
ing new therapeutic targets in AD. In this vein, over
the last few decades, the cerebral adrenergic system
has emerged as a potential candidate for further inves-
tigation in AD.
ADRENERGIC SYSTEM IN ALZHEIMER’S
DISEASE
It is well established that LC is the main nore-
pinephrine source in the central nervous system (CNS),
providing an extensive network of neuronal projections
to all major brain regions, including the neocortex
and hippocampus [6]. Several studies have indicated
that LC degeneration might have a role in AD patho-
genesis. In fact, numerous postmortem studies on
AD brains have documented an early LC degenera-
tion during the course of AD [7, 8]. Moreover, other
studies have observed that LC neuronal loss in AD
patients is paralleled by a significant reduction in
cortical norepinephrine concentration that is corre-
lated with cognitive impairment [9], while others have
demonstrated that in the LC of AD subjects, a sig-
nificant decrease in the norepinephrine transporter is
observed, and this decrease correlates with the pro-
gression of the disease [10]. However, other studies
reported an increased norepinephrine concentration
in cerebrospinal fluid [11], suggesting that in AD
brain, there is a compensation occurring in the remain-
ing noradrenergic neurons [12]. In addition, it has
been observed that degeneration of LC neurons can
occur in patients with mild cognitive impairment [13].
Moreover, along with its role as a neurotransmitter,
norepinephrine has also been recently described to
exert anti-inflammatory actions within the CNS, since
the decrease of norepinephrine in LC projection areas
has been shown to facilitate the inflammatory reaction
of microglial cells in AD [6] and to exacerbate neu-
roinflammation induced by the deposition of amyloid
peptides [14].
-ADRENERGIC RECEPTORS (-AR) AND
ALZHEIMER’S DISEASE
The effects of norepinephrine are mediated by the
modulation of AR in brain, with both - and -AR
playing an important role in brain neurotransmission.
Functional studies of AR in human brain have focused
mainly on 2-receptors regulating neurotransmitter
release [15, 16], although all three known subtypes
of -ARs (1-AR, 2-AR, and 3-AR) are found in
brain, with the 3-AR subtype having limited expres-
sion [17]. Some imaging studies have documented
that -AR are located in the cerebral cortex, nucleus
accumbens, and striatum. At lower density, they are
also present in amygdala, hippocampus, and cerebel-
lum. In particular, 2-AR have a role in the regulation
of glial proliferation during ontogenic development,
after trauma, and in neurodegenerative diseases, while
1-AR density is affected by stress, in several mood
disorders (depression, schizophrenia) and during treat-
ment with antidepressants [18]. Moreover, it has been
demonstrated that both 1- and 2-ARs are present on
rat microglial cells [19].
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-ARs are members of the large family of
seven membrane-spanning, G-protein-coupled recep-
tors (GPCR). Although they respond to the same
ligands (norepinephrine and epinephrine) -ARs dif-
fer significantly in the types of cellular responses they
mediate [20, 21]. Their agonist-mediated activation
catalyzes the exchange of GTP for GDP on the G-
subunit of G proteins, resulting in the dissociation of
the heterotrimer into active G- and G-subunits,
which are competent to signal independently. The
activated G-subunit dissociates from the G protein
complex and stimulates (Gs) or inhibits (Gi) adeny-
lyl cyclase, and therefore modulates the intracellular
amount of cyclic AMP (cAMP) [22].
Moreover, the dissociation of the G subunit is
able to facilitate the juxtaposition of AR and G-protein
receptor kinases (GRKs), which ultimately mediate the
phosphorylation of AR [23]. GRK-mediated phospho-
rylation results in agonist-dependent desensitization
(homologous desensitization) of ARs and promotes
the binding of the cytosolic proteins arrestins. Once
bound to the receptor, arrestins interdict further
G-protein coupling and target the activated receptor
for endocytosis (downregulation) [24].
Over the last few decades, there has been growing
interest in exploring the potential implications of -
ARs in the pathogenesis of AD. In the late 1980 s,
Kalaria and colleagues found that in AD subjects
selective changes in the number of -ARs occurred
in different brain regions and these changes were
paralleled by reduction in the number of LC cells
and norepinephrine concentrations in putamen and
frontal cortex [25]. Importantly, -ARs have also been
implicated in A formation in AD. In fact, it has
been shown that stimulation of AR by norepinephrine,
coupled with increased cAMP formation, resulted in
APP overexpression in rat astrocytes. Interestingly,
the increase in APP caused by norepinephrine treat-
ment was inhibited by the-AR antagonist propranolol
[26]. In 2006, Igbavboa et al. demonstrated that A
stimulated cAMP formation, and this stimulation was
inhibited by selective -AR antagonists in mouse pri-
mary cortical astrocytes. Furthermore, this effect of
A on cAMP levels was associated with an increase in
apolipoprotein E levels which in turn was inhibited by
selective -AR antagonists. The authors suggest that
a potential association between -AR and apolipopro-
tein E homeostasis could be an important mechanism
in counteracting A-induced neurotoxicity in astro-
cytes [27]. Further insight on the important role of
-AR in amyloid formation came from a study by Ni
and colleagues. In particular, they demonstrated that
the activation of 2-AR increases A production in
vitro and amyloid plaque formation in vivo by enhanc-
ing -secretase activity. The mechanism proposed in
this study involved the association of 2-AR with
presenilin-1 and required agonist-induced endocytosis
of 2-AR. Moreover, chronic treatment with 2-AR
agonists increased cerebral amyloid plaques, while the
2-AR-selective antagonist ICI 118,551 ameliorated
amyloid plaque pathology in mouse models of AD,
suggesting that abnormal 2-AR activation might con-
tribute to A accumulation in AD pathogenesis (Fig. 1)
[28]. Similar results were obtained in a mouse model
of acute restraint stress, in which administration of
the 2-AR selective agonist clenbuterol enhanced the
stress-induced A peptides production, while the 2-
AR-selective antagonist ICI 118,551 reduced it [29].
More recently, Wang and colleagues demonstrated that
in primary cortical neurons, A is able to bind to
2-AR and to induce receptors internalization and
degradation. This process is prevented by pretreat-
ment with -AR antagonist timolol and is dependent
on GRK2-mediated receptor phosphorylation [30]. In
addition, genetic studies have shown a correlation
between -AR polymorphisms and AD. In particu-
lar, Yu and colleagues investigated the association of
two polymorphisms in the 2-AR gene (Gly16Arg and
Gln27Glu) with the risk of late onset AD in a Chinese
population. Their results indicate that both2-AR gene
variants were associated with an increased risk of late
onset AD, and they also showed a significant corre-
lation with the apolipoprotein E 4 allele, suggesting
that the Gly16 and Gln27 variants are associated with
the development of AD, and might also interact with
apolipoprotein E 4 status [31].
Additional evidence on the importance of the adren-
ergic system in AD came from studies on AR blockers.
In particular, it has been demonstrated that carvedilol,
a nonselective - and -AR blocker, significantly
reduced oligomerization and deposition of Apeptides
in the cerebral cortex and hippocampus of transgenic
murine model of AD [32]. The same authors also
showed that carvedilol is able to increase basal synap-
tic transmission and long term potentiation in AD
mice, thus improving neuronal plasticity [33]. Fur-
ther data emerged from clinical studies examining the
association of cardiovascular medication use and AD
incidence. Interestingly, in the Dementia Progression
Study of the Cache County Study, Rosenberg demon-
strated that use of statins and-blockers was associated
with a slower annual rate of functional decline in this
AD population, while other cardiovascular drugs did
not affect the functional decline [34].
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Fig. 1. Mechanisms of action for2 adrenergic receptor (2-AR) and G-protein-coupled receptor kinase 2 (GRK2) in amyloid- (A) production
as proposed by Ni et al. [28]. A) G-protein-dependent 2-AR signaling pathway. Receptor activation by norepinephrine (NE) leads to stimulation
of adenylate cyclase (AC) and elevated cAMP. B) Agonist-bound 2-AR phosphorylation by GRK2 induces endocytosis of the 2-AR/-
secretase complex. In lysosomes -secretase activity is increased, leading to increased production of A. APP, amyloid- protein precursor;
PS, presenilin; Nic, nicastrin; Pen-2, presenilin enhancer 2; Aph-1, anterior pharynx-defective 1.
Despite the fact that the evidence currently available
is in some cases conflicting, taken together, the findings
discussed above suggest that -ARs might represent
a novel target in AD treatment that deserves further
exploration and whose role needs definite clarification.
GRK2 AND ALZHEIMER’S DISEASE
Besides ARs alterations, several lines of evidence
have suggested that there is a widespread dysfunction
in post-receptor components of GPCR signaling in AD
brain, occurring at the receptor-G protein interface that
is the site of action of GRKs [35].
The GRKs are a family of cytosolic serine/threonine
kinases consisting of seven isoforms that share
structural and functional similarities. Their primary
function is to desensitize activated GPCRs and tar-
get them for internalization. While some GRKs are
expressed in a wide variety of tissues, others display a
more restricted expression pattern [24].
Recent studies on AD pathogenetic mechanisms
have primarily focused on the possible involvement
of GRK2 and GRK5 in GPCR-G protein interaction
dysfunction of the disease.
As for GRK5, different studies have demonstrated
that in AD brain, A deposition can lead to reduced
membrane GRK5 levels. The so-called “GRK5
deficiency” impairs muscarinic receptors regulation,
ultimately leading to reduced acetylcholine release and
neuronal degeneration [36].
GRK2, also known as -AR kinase 1 (ARK1),
is the most abundant GRK in the heart, and its lev-
els are increased in different cardiovascular diseases
associated with impaired cardiac function [37–42]. In
brain, GRK2 is widely distributed, as it is found in
both postsynaptic densities and presynaptic axon ter-
minals consistent with a general role of GRK2 in the
desensitization of synaptic receptors [43].
The first to examine the possible involvement of
GRK2 in AD pathology were Suo and colleagues.
These authors evaluated the molecular mechanisms
underlying the effects of soluble A in murine
microglial cells and in an AD transgenic mouse
model. They discovered that soluble A can poten-
tiate, in a dose-dependent manner, microglial release
of inflammatory cytokines and, more importantly, they
also found that A treatment of microglial cells in
vitro decreased membrane-bound levels of GRK2 and
GRK5, leading to cytosolic GRK accumulation. This
process resulted in retarded GPCR desensitization and
prolonged GPCR signaling, leading to receptors hyper-
activity. Analysis of early-onset AD transgenic mice
revealed that while total brain GRK2 levels increased,
the kinase in the membrane fraction was significantly
reduced. Furthermore, the GRK abnormality observed
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in vivo was associated with the very early increase of
brain soluble A levels and it occurred before the onset
of cognitive decline. These observations imply that the
GRK abnormality may be an early pathogenetic event
manifesting at prodromic and early stages of AD that
is closely associated with very early accumulation of
brain soluble A [44]. Another report demonstrated
that GRK2 colocalized with neurofibrillary tangles in
AD mixed with Lewy body disease and AD human
brains, but was not present in Lewy bodies [45].
An important aspect of GPCR signaling is that sys-
tem properties in circulating white blood cells appear to
mirror those observed in solid tissues. In this regard,
our group showed that lymphocyte GRK2 levels are
well correlated to cardiac protein concentrations in
patients with heart failure [46].
According to this concept, we examined for the first
time the role of lymphocyte GRK2 in patients with AD.
In our study, we evaluated GRK2 mRNA levels and
protein expression in peripheral blood lymphocytes of
AD patients with mild or moderate/severe cognitive
impairment and in age-matched healthy subjects. We
found that both GRK2 mRNA and protein expression
were significantly higher in AD patients lymphocytes
compared to controls. Furthermore, lymphocyte GRK2
levels were significantly correlated to the degree of
cognitive decline. Importantly, these data suggest that
lymphocyte GRK2 could emerge as a novel biological
marker of this syndrome [47].
As discusses above, increasing evidence strongly
support the hypothesis that vascular damage is an early
contributor to the development of AD. In fact, vascu-
lar injury and parenchymal inflammation perpetuate
protein aggregation and oxidation in brain. Moreover,
AD and vascular dementia have several risk factors in
common, including hypertension, aging, and dyslipi-
demia, and it is well established that cardiovascular
risk factors are in part responsible for the neurovascu-
lar unit dysfunction observed both in AD and vascular
dementia [48]. Based on this hypothesis, Obrenovich
and colleagues explored, by morphological studies,
cellular and subcellular localization of GRK2 in the
early phases of AD and in ischemia-reperfusion injury
models of chronic brain hypoperfusion, that mimic
mild cognitive impairment and vascular changes in AD
pathology. They demonstrated the early overexpres-
sion of GRK2 in the cerebrovasculature, particularly
in endothelial cells following chronic hypoperfusion.
They also found a significant increase in GRK2
immunoreactivity in endothelial cells of AD patients,
which preceded any amyloid deposition. Thus they
propose to consider AD and AD-like pathology as
disorders of the cerebrovasculature and to use
GRK2 as an early marker of cerebrovascular aging
complications in age-associated diseases involv-
ing cerebrovascular abnormalities, neurodegeneration,
and cognitive impairment before any amyloid deposi-
tion can be seen [49].
FUTURE PERSPECTIVES AND
THERAPEUTIC OPPORTUNITIES
Besides established treatment for AD and novel ther-
apeutic strategies currently pursued, such as secretase-
modulating drugs or A-targeted immunotherapy [50],
several pathogenic mechanisms involved in AD still
need to be clarified.
In this vein,-AR and GRKs are two possible targets
that deserve further exploration in this field. AR sys-
tem and its regulation by GRK have a well-established
role in cardiovascular diseases and there are numerous
parallels that can be drawn between neurodegenera-
tive and cerebrovascular disorders [4, 48]. In the last
decades, in fact, the “neuroncentric” hypothesis for AD
pathogenesis has gradually left space to the neurovas-
cular hypothesis, in which -ARs and GRK2 could
certainly play a role that deserves further insight. Stud-
ies on the use of -blockers have shown that these
drugs are able to slow cognitive decline in AD patients
but the underlying mechanism of action has not been
explored, neither the effects of -blockers on brain
GRK2 levels [34]. As for GRK2 modulation in AD,
evidence available have shown that GRK2 inhibition,
via the ARKct peptide, is able to block the A-
induced 2AR internalization in vitro, but the effects
of GRK2 on A accumulation have not yet been inves-
tigated [30]. Particularly intriguing is the finding that
GRK2 is associated with vascular damage in AD [49].
This latter evidence suggests that GRK2 involvement
in AD could also be A-independent, thus representing
an alternative therapeutic target in the disease. More-
over, a recent study identified the selective serotonin
reuptake inhibitor paroxetine as a direct inhibitor of
GRK2 activity [51]. If this kinase emerged as a key
factor involved in AD pathogenesis, then the possibil-
ity to use selective drugs as paroxetine to modulate
its expression would have a tremendous therapeutic
impact. In addition, lymphocyte GRK2 levels have
been shown to correlate with cognitive status of AD
patients [47], thus peripheral levels of the kinase could
be used as an easily accessible biomarker to monitor
patients’ cognitive function and response to specific
therapies.
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CONCLUSIONS
AD is a major and growing public health problem
and medications currently available are symptomatic
drugs that do not significantly affect the progression
of the disease. Hence, there is an urgent medical need
for the development of new therapeutic strategies tar-
geting different pathogenic mechanisms involved in
AD onset and progression. In this view, the -AR sys-
tem emerges as a novel and interesting player in the
pathogenesis of AD, for its involvement both in the
neuronal/glial alterations and vascular modifications
occurring in AD. Moreover, the availability of several
molecules acting on -ARs, together with long-term
experience with their use, makes -AR signaling and
GRK modulation valuable targets for AD treatment.
Nevertheless, additional preclinical and clinical studies
are required to clearly assess the role of -AR system-
modulating drugs as feasible tools for AD therapy.
DISCLOSURE STATEMENT
Authors’ disclosures available online (http://www.j-
alz.com/disclosures/view.php?id=1564).
REFERENCES
[1] Ward A, Crean S, Mercaldi CJ, Collins JM, Boyd D, Cook
MN, Arrighi HM (2012) Prevalence of apolipoprotein E4
genotype and homozygotes (APOE e4/4) among patients
diagnosed with Alzheimer’s disease: A systematic review and
meta-analysis. Neuroepidemiology 38, 1-17.
[2] Yu JT, Wang ND, Ma T, Jiang H, Guan J, Tan L (2011) Roles of
-adrenergic receptors in Alzheimer’s disease: Implications
for novel therapeutics. Brain Res Bull 84, 111-117.
[3] Querfurth HW, LaFerla FM (2010) Alzheimer’s disease.
N Engl J Med 362, 329-344.
[4] Zlokovic BV (2011) Neurovascular pathways to neurodegen-
eration in Alzheimer’s disease and other disorders. Nat Rev
Neurosci 12, 723-738.
[5] Lyness SA, Zarow C, Chui HC (2003) Neuron loss in key
cholinergic and aminergic nuclei in Alzheimer disease: A
meta-analysis. Neurobiol Aging 24, 1-23.
[6] Heneka MT, Nadrigny F, Regen T, Martinez-Hernandez A,
Dumitrescu-Ozimek L, Terwel D, Jardanhazi-Kurutz D, Wal-
ter J, Kirchhoff F, Hanisch UK, Kummer MP (2010) Locus
ceruleus controls Alzheimer’s disease pathology by modulat-
ing microglial functions through norepinephrine. Proc Natl
Acad Sci U S A 107, 6058-6063.
[7] Zarow C, Lyness SA, Mortimer JA, Chui HC (2003) Neuronal
loss is greater in the locus coeruleus than nucleus basalis and
substantia nigra in Alzheimer and Parkinson diseases. Arch
Neurol 60, 337-341.
[8] Haglund M, Sjo¨beck M, Englund E (2006) Locus ceruleus
degeneration is ubiquitous in Alzheimer’s disease: Possible
implications for diagnosis and treatment. Neuropathology 26,
528-532.
[9] Matthews KL, Chen CP, Esiri MM, Keene J, Minger SL, Fran-
cis PT (2002) Noradrenergic changes, aggressive behavior,
and cognition in patients with dementia. Biol Psychiatry 51,
407-416.
[10] Gulya´s B, Brockschnieder D, Nag S, Pavlova E, Ka´sa P,
Beliczai Z, La´gra´di A, Gulya K, Thiele A, Dyrks T, Halldin
C (2010) The norepinephrine transporter (NET) radioli-
gand (S,S)-[18F]FMeNER-D2 shows significant decreases
in NET density in the human brain in Alzheimer’s disease:
A post-mortem autoradiographic study. Neurochem Int 56,
789-798.
[11] Raskind MA, Peskind ER, Holmes C, Goldstein DS
(1999) Patterns of cerebrospinal fluid catechols support
increased central noradrenergic responsiveness in aging and
Alzheimer’s disease. Biol Psychiatry 46, 756-765.
[12] Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER,
Raskind MA (2006) Compensatory changes in the noradren-
ergic nervous system in the locus ceruleus and hippocampus of
postmortem subjects with Alzheimer’s disease and dementia
with Lewy bodies. J Neurosci 26, 467-478.
[13] Grudzien A, Shaw P, Weintraub S, Bigio E, Mash DC, Mesu-
lam MM (2007) Locus coeruleus neurofibrillary degeneration
in aging, mild cognitive impairment and early Alzheimer’s
disease. Neurobiol Aging 28, 327-335.
[14] Jardanhazi-Kurutz D, Kummer MP, Terwel D, Vogel K, Thiele
A, Heneka MT (2011) Distinct adrenergic system changes
and neuroinflammation in response to induced locus ceruleus
degeneration in APP/PS1 transgenic mice. Neuroscience 176,
396-407.
[15] Raiteri M (2006) Functional pharmacology in human brain.
Pharmacol Rev 58, 162-193.
[16] Lymperopoulos A, Rengo G, Koch WJ (2007) Adrenal
adrenoceptors in heart failure: Fine-tuning cardiac stimula-
tion. Trends Mol Med 13, 503-511.
[17] Rainbow TC, Parsons B, Wolfe BB (1984) Quantitative
autoradiography of beta 1- and beta 2-adrenergic receptors
in rat brain. Proc Natl Acad Sci U S A 81, 1585-1589.
[18] van Waarde A, Vaalburg W, Doze P, Bosker FJ, Elsinga PH
(2004) PET imaging of beta-adrenoceptors in human brain:
A realistic goal or a mirage? Curr Pharm Des 10, 1519-1536.
[19] Tanaka KF, Kashima H, Suzuki H, Ono K, Sawada M (2002)
Existence of functional beta1- and beta2-adrenergic receptors
on microglia. J Neurosci Res 70, 232-237.
[20] Lefkowitz RJ (2007) Seven transmembrane receptors: Some-
thing old, something new. Acta Physiol (Oxf) 190, 9-19.
[21] Rengo G, Zincarelli C, Femminella G, Liccardo D, Pagano
G, de Lucia C, Altobelli G, Cimini V, Ruggiero D, Perrone-
Filardi P, Gao E, Ferrara N, Lymperopoulos A, Koch W,
Leosco D (2012) Myocardial (2)-adrenoceptor gene deliv-
ery promotes coordinated cardiac adaptive remodelling and
angiogenesis in heart failure.Br JPharmacol 166, 2348-2361.
[22] Leineweber K, Rohe P, Beilfuss A, Wolf C, Sporkmann H,
Bruck H, Jakob HG, Heusch G, Philipp T, Brodde OE (2005)
G-protein-coupled receptor kinase activity in human heart
failure: Effects of beta-adrenoceptor blockade. Cardiovasc
Res 66, 512-519.
[23] Rengo G, Lymperopoulos A, Leosco D, Koch WJ (2011)
GRK2 as a novel gene therapy target in heart failure. J Mol
Cell Cardiol 50, 785-792.
[24] Rengo G, Perrone-Filardi P, Femminella GD, Liccardo D,
Zincarelli C, de Lucia C, Pagano G, Marsico F, Lymperopou-
los A, Leosco D (2012) Targeting the -adrenergic receptor
system through G-protein-coupled receptor kinase 2: A new
paradigm for therapy and prognostic evaluation in heart fail-
ure: From bench to bedside. Circ Heart Fail 5, 385-391.
G.D. Femminella et al. / Adrenergic System in Alzheimer’s Disease 347
[25] Kalaria RN, Andorn AC, Tabaton M, Whitehouse PJ, Harik
SI, Unnerstall JR (1989) Adrenergic receptors in aging and
Alzheimer’s disease: Increased beta 2-receptors in prefrontal
cortex and hippocampus. J Neurochem 53, 1772-1781.
[26] Lee RK, Araki W, Wurtman RJ (1997) Stimulation of amyloid
precursor protein synthesis by adrenergic receptors coupled
to cAMP formation. Proc Natl Acad Sci U S A 94, 5422-5426.
[27] Igbavboa U, Johnson-Anuna LN, Rossello X, Butterick
TA, Sun GY, Wood WG (2006) Amyloid beta-protein1-42
increases cAMP and apolipoprotein E levels which are inhib-
ited by beta1 and beta2-adrenergic receptor antagonists in
mouse primary astrocytes. Neuroscience 142, 655-660.
[28] Ni Y, Zhao X, Bao G, Zou L, Teng L, Wang Z, Song M, Xiong
J, Bai Y, Pei G (2006) Activation of beta2-adrenergic receptor
stimulates gamma-secretase activity and accelerates amyloid
plaque formation. Nat Med 12, 1390-1396.
[29] Yu NN, Wang XX, Yu JT, Wang ND, Lu RC, Miao D, Tian Y,
Tan L (2010) Blocking beta2-adrenergic receptor attenuates
acute stress-induced amyloid beta peptides production. Brain
Res 1317, 305-310.
[30] Wang D, Yuen EY, Zhou Y, Yan Z, Xiang YK (2011) Amyloid
beta peptide-(1-42) induces internalization and degradation
of beta2 adrenergic receptors in prefrontal cortical neurons.
J Biol Chem 286, 31852-31863.
[31] Yu JT, Tan L, Ou JR, Zhu JX, Liu K, Song JH, Sun YP
(2008) Polymorphisms at the beta2-adrenergic receptor gene
influence Alzheimer’s disease susceptibility. Brain Res 1210,
216-222.
[32] Wang J, Ono K, Dickstein DL, Arrieta-Cruz I, Zhao W, Qian
X, Lamparello A, Subnani R, Ferruzzi M, Pavlides C, Ho
L, Hof PR, Teplow DB, Pasinetti GM (2011) Carvedilol as a
potential novel agent for the treatment of Alzheimer’s disease.
Neurobiol Aging 32, 1-12.
[33] Arrieta-Cruz I, Wang J, Pavlides C, Pasinetti GM (2010)
Carvedilol reestablishes long-term potentiation in a mouse
model of Alzheimer’s disease. J Alzheimers Dis 21, 649-654.
[34] Rosenberg PB, Mielke MM, Tschanz J, Cook L, Corcoran
C, Hayden KM, Norton M, Rabins PV, Green RC, Welsh-
Bohmer KA, Breitner JC, Munger R, Lyketsos CG (2008)
Effects of cardiovascular medications on rate of functional
decline in Alzheimer disease. Am J Geriatr Psychiatry 16,
883-892.
[35] Fowler CJ, Garlind A, O’Neill C, Cowburn RF (1996)
Receptor-effector coupling dysfunctions in Alzheimer’s dis-
ease. Ann N Y Acad Sci 786, 294-304.
[36] Suo WZ, Li L (2010) Dysfunction of G protein-coupled recep-
tor kinases in Alzheimer’s disease. ScientiﬁcWorldJournal 10,
1667-1678.
[37] Rengo G, Lymperopoulos A, Zincarelli C, Donniacuo M,
Soltys S, Rabinowitz JE, Koch WJ (2009) Myocardial
adeno-associated virus serotype 6-betaARKct gene therapy
improves cardiac function and normalizes the neurohormonal
axis in chronic heart failure. Circulation 119, 89-98.
[38] Raake PW, Vinge LE, Gao E, Boucher M, Rengo G, Chen
X, DeGeorge BR Jr, Matkovich S, Houser SR, Most P, Eck-
hart AD, Dorn GW 2nd, Koch WJ (2008) G protein-coupled
receptor kinase 2 ablation in cardiac myocytes before or after
myocardial infarction prevents heart failure. Circ Res 103,
413-422.
[39] Lymperopoulos A, Rengo G, Funakoshi H, Eckhart AD, Koch
WJ (2007) Adrenal GRK2 upregulation mediates sympathetic
overdrive in heart failure. Nat Med 13, 315-323.
[40] Rengo G, Lymperopoulos A, Zincarelli C, Femminella G,
Liccardo D, Pagano G, de Lucia C, Cannavo A, Gargiulo P,
Ferrara N, Perrone Filardi P, Koch W, Leosco D (2012) Block-
ade of -adrenoceptors restores the GRK2-mediated adrenal
(2) -adrenoceptor-catecholamine production axis in heart
failure. Br J Pharmacol 166, 2430-2440.
[41] Rengo G, Leosco D, Zincarelli C, Marchese M, Corbi G,
Liccardo D, Filippelli A, Ferrara N, Lisanti MP, Koch WJ,
Lymperopoulos A (2010) Adrenal GRK2 lowering is an
underlying mechanism for the beneficial sympathetic effects
of exercise training in heart failure. Am J Physiol Heart Circ
Physiol 298, 2032-2038.
[42] Lymperopoulos A, Rengo G, Gao E, Ebert SN, Dorn GW
2nd, Koch WJ (2010) Reduction of sympathetic activity via
adrenal-targeted GRK2 gene deletion attenuates heart failure
progression and improves cardiac function after myocardial
infarction. J Biol Chem 285, 16378-16386.
[43] Erdtmann-Vourliotis M, Mayer P, Ammon S, Riechert U,
Ho¨llt V (2001) Distribution of G-protein-coupled receptor
kinase (GRK) isoforms 2, 3, 5 and 6 mRNA in the rat brain.
Brain Res Mol Brain Res 95, 129-137.
[44] Suo Z, Wu M, Citron BA, Wong GT, Festoff BW (2004)
Abnormality of G-protein-coupled receptor kinases at prodro-
mal and early stages of Alzheimer’s disease: An association
with early beta-amyloid accumulation. J Neurosci 24, 3444-
3452.
[45] Takahashi M, Uchikado H, Caprotti D, Weidenheim KM,
Dickson DW, Ksiezak-Reding H, Pasinetti GM (2006) Iden-
tification of G-protein coupled receptor kinase 2 in paired
helical filaments and neurofibrillary tangles. J Neuropathol
Exp Neurol 65, 1157-1169.
[46] Iaccarino G, Barbato E, Cipolletta E, De Amicis V, Mar-
gulies KB, Leosco D, Trimarco B, Koch WJ (2005) Elevated
myocardial and lymphocyte GRK2 expression and activity in
human heart failure. Eur Heart J 26, 1752-1758.
[47] Leosco D, Fortunato F, Rengo G, Iaccarino G, Sanzari E,
Golino L, Zincarelli C, Canonico V, Marchese M, Koch
WJ, Rengo F (2007) Lymphocyte G-protein-coupled receptor
kinase-2 is upregulated in patients with Alzheimer’s disease.
Neurosci Lett 415, 279-282.
[48] Iadecola C (2010) The overlap between neurodegenerative
and vascular factors in the pathogenesis of dementia. Acta
Neuropathol 120, 287-296.
[49] Obrenovich ME, Smith MA, Siedlak SL, Chen SG, de la Torre
JC, Perry G, Aliev G (2006) Overexpression of GRK2 in
Alzheimer disease and in a chronic hypoperfusion rat model
is an early marker of brain mitochondrial lesions. Neurotox
Res 10, 43-56.
[50] van Marum RJ (2008) Current and future therapy in
Alzheimer’s disease. Fundam Clin Pharmacol 22, 265-274.
[51] Thal DM, Homan KT, Chen J, Wu EK, Hinkle PM, Huang
ZM, Chuprun JK, Song J, Gao E, Cheung JY, Sklar LA, Koch
WJ, Tesmer JJ (2012) Paroxetine is a direct inhibitor of G
protein-coupled receptor kinase 2 and increases myocardial
contractility. ACS Chem Biol 7, 1830-1839.
View publication stats
